Cancer, a complex disease characterized by uncontrolled cellular proliferation, arises from a multitude of genetic and epigenetic alterations.  Significant advances in genomics and bioinformatics have revolutionized our understanding of the genetic basis of cancer, paving the way for personalized medicine approaches. This research paper explores the evolving landscape of cancer genetics and its implications for targeted therapies and improved patient outcomes.  We review recent progress in identifying driver mutations across various cancer types, including the identification of novel oncogenes and tumor suppressor genes through next-generation sequencing and advanced bioinformatic analyses.  Further, we examine the impact of these discoveries on the development of personalized therapeutic strategies, focusing on targeted therapies, immunotherapy, and the challenges of overcoming drug resistance.  The application of pharmacogenomics, which analyzes the interplay between individual genetic variations and drug response, is also discussed.  Finally, we consider the ethical and practical implications of implementing personalized cancer medicine, encompassing issues of accessibility, cost-effectiveness, and the need for robust clinical trial designs to validate emerging targeted therapies.